-
Sci Rep: Scientists hope to use novel epigenetic biomarker to predict infant's risk of preterm birth
Time of Update: 2022-05-23
Recently, in a research report titled "Preterm birth buccal cell epigenetic biomarkers to facilitate preventative medicine" published in the international journal Scientific Reports, scientists from Indiana University and other institutions found in the cheek cells of the parents of premature babies.
-
The world's first medical device suitable for a specific phobia (acrophobia) has been approved as a Class II medical device
Time of Update: 2022-05-23
Explore the application of digital therapy in mental health to provide new tools for health careThe "Specific Fear Psychological Rehabilitation Training Software" jointly developed by Ningdong Medical is the first Class II medical device product successfully transformed and approved by the Shanghai Mental Health Center, and it is also the first attempt of the two parties to cooperate in the field of mental health .
-
Nat Commun: Microbiota of the buffalo digestive tract
Time of Update: 2022-05-23
Researchers used a metagenomic approach to study the microbial community of the buffalo digestive tract .
In conclusion, this study provides insights into microbial functions and interactions in different parts of the buffalo digestive tract through a comprehensive analysis of microbial genomes and encoded proteins .
-
Biositu and BeiGene Reach a Collaboration on the Licensed Use of RenMab/RenLite Fully Human Antibody in Mice
Time of Update: 2022-05-23
BeiGene”) licenses the use of the RenMab®/RenLite® fully human antibody mouse platform with independent intellectual property rights of Biositu to develop various types of antibody drugs such as fully human monoclonal antibodies and double antibodies .
-
Nat Genet: Delaying DNA replication fork speeds leads to cell fate changes and enhances cell reprogramming efficiency
Time of Update: 2022-05-23
The relevant research results were published online in the journal Nature Genetics on March 7, 2022, with the title of "DNA replication fork speed underlies cell fate changes and promotes reprogramming" .
DNA replication fork speed underlies cell fate changes and promotes reprogramming.
-
Dexmedetomidine for Bipolar Disorder-Associated Acute Agitation Phase III Positive Results Published
Time of Update: 2022-05-23
On the key secondary endpoint, both sublingual dexmedetomidine treatment groups showed significant improvements in PEC scores as early as 20 minutes after dosing, compared with placebo .
-
The U.S. Food and Drug Administration (FDA) approves Opdivo(R) (nivolumab) in combination with chemotherapy for the neoadjuvant treatment of selected adult patients with resectable non-small cell lung cancer
Time of Update: 2022-05-23
SHANGHAI, March 6, 2022 /PRNewswire/ -- On March 4, 2022, Bristol-Myers Squibb (announced that the U. S. Food and Drug Administration (FDA) has approved Opdivo® (nivolumab) 360 mg (intravenous) in co
-
Otolide(R) (empagliflozin) becomes the first and currently only therapy approved in Europe for the treatment of symptomatic adults with chronic heart failure regardless of their ejection fraction
Time of Update: 2022-05-23
This groundbreaking approval expands the existing indications for Otolide® to include the treatment of adults with heart failure with preserved ejection fraction (HFpEF), a patient population with unmet medical needs, There are no previously approved therapies for this group in Europe 24 February 2022 Otolide® received marketing approval from the U.
-
Great roundup!
Time of Update: 2022-05-23
007Recently, researchers from Nanjing Medical University published a paper entitled "Novel insights into the interaction between N6-methyladenosine modification and circular RNA" in the journal Molecular Therapy: Nucleic Acids.
-
Nat Commun: Scientists Find Obesity Induces Islet Inflammation!
Time of Update: 2022-05-23
A research paper titled "Accumulation of microbial DNAs promotes to islet inflammation and β cell abnormalities in obesity in mice" published on Nat Commun specifically elucidates this mechanism .
-
Broad Becomes CRIPSR Patent Owner Intellia Faces Patent Infringement
Time of Update: 2022-05-23
biotech company Intellia and collaborator Regeneron today announced results from a second clinical trial of the ATTR gene-editing therapy NTLA-2001, with nine patients receiving one input .
-
Takeda Announces Collaboration to Develop Reproducible, Non-Viral Gene Therapies
Time of Update: 2022-05-23
On February 23, Takeda and Code Biotherapeutics (Code Bio) jointly announced a collaboration and option agreement whereby Takeda will utilize Code Bio's proprietary 3DNA-targeted non-viral gene drug delivery platform to design and develop treatments for rare diseases Indications for gene therapy .
-
"Nature" heavy: Chinese scientists crack the mechanism of action of metformin
Time of Update: 2022-05-23
▲Metformin binds to PEN2 to activate AMPK (Image source: Reference [1])Next, the research team revealed the pathway by which metformin works based on this newly discovered target .
-
Great roundup!
Time of Update: 2022-05-23
gov/35222443/Recently, researchers from Sichuan University published a review article entitled "The Role of Long Non-Coding RNAs in the Tumor Immune Microenvironment" in Frontiers in Immunology.
The Role of Long Non-Coding RNAs in the Tumor Immune Microenvironment.
-
Code Announces R&D Agreement with Takeda to Develop Non-Viral Vector Gene Therapies
Time of Update: 2022-05-23
References:[1] Code Biotherapeutics Announces Collaboration with Takeda to Use Proprietary 3DNA Genetic Medicine Delivery Platform to Design and Develop Gene Therapies for Rare Diseases.
-
Nat Aging: Cell regeneration therapy can safely reverse aging in mice
Time of Update: 2022-05-23
"We are delighted that we can use this approach to slow aging in normal animals throughout the lifespan," said co-corresponding author Professor Juan Carlos Izpisua Belmonte of the Gene Expression Laboratory at the Salk Institute for Biological Studies .
-
JCI: Uncovering novel molecular mechanisms of the body's defense against cancer progression
Time of Update: 2022-05-23
Recently, in a research report titled "LC3-associated phagocytosis in bone marrow macrophages suppresses acute myeloid leukemia progression through STING activation" published in the international journal Journal of Clinical Investigation, scientists from the University of East Anglia and other institutions through research Uncovering how the body's immune system is induced to attack cancer cells could lead to new treatments for leukemia patients .
-
Fotivda milestone 5-year follow-up data: efficacy beats Nexavar!
Time of Update: 2022-05-23
Milestone 5-year follow-up data show patients treated with Fotivda achieved long-term disease compared with Bayer's targeted cancer drug Nexavar (Nexavar, generic name: sorafenib) in 3- and 4-line RCC patients Progression-free survival (PFS) was 5 times more likely .
-
"Delta Chron" variant confirmed for the first time
Time of Update: 2022-05-23
Science and Technology Daily (Reporter Liu Xia) According to a report by the American Fun Science website on March 11, French scientists have confirmed for the first time through genome sequencing that the new coronavirus "deltacron" variant that has previously attracted a lot of attention does exist.
-
Two clinical failures of Opdivo combined with bempeg in the treatment of melanoma may spread to other cancer trials of "O drug"
Time of Update: 2022-05-22
Jonathan Zalevsky, chief research and development officer at Nektar, said that he will continue to await preliminary results from the first two ongoing studies in renal cell carcinoma and urothelial carcinoma, which are currently expected to be completed in the first half of 2022, and look forward to working with BMS to evaluate these other studies.
